Zacks Research Issues Optimistic Forecast for PAHC Earnings

Phibro Animal Health Corporation (NASDAQ:PAHC) – Equities researchers at Zacks Research increased their FY2026 earnings per share (EPS) estimates for Phibro Animal Health in a research report issued on Wednesday, May 20th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $3.04 for the year, up from their prior forecast of $2.99. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $3.06 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2026 earnings at $0.68 EPS, Q2 2027 earnings at $0.84 EPS, Q3 2027 earnings at $0.75 EPS, Q4 2027 earnings at $0.80 EPS, FY2027 earnings at $3.17 EPS, Q1 2028 earnings at $0.81 EPS, Q2 2028 earnings at $0.91 EPS, Q3 2028 earnings at $0.81 EPS and FY2028 earnings at $3.34 EPS.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The business had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS.

A number of other brokerages have also recently weighed in on PAHC. Citigroup dropped their price target on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Weiss Ratings cut Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 8th. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research report on Friday, February 6th. Finally, Wall Street Zen cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $38.80.

Phibro Animal Health Trading Down 1.0%

Shares of PAHC stock opened at $33.46 on Friday. Phibro Animal Health has a fifty-two week low of $22.51 and a fifty-two week high of $60.08. The stock has a market cap of $1.36 billion, a P/E ratio of 14.36, a P/E/G ratio of 0.51 and a beta of 0.61. The business has a fifty day simple moving average of $50.63 and a 200-day simple moving average of $46.08. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd will be given a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Wednesday, June 3rd. Phibro Animal Health’s dividend payout ratio (DPR) is currently 20.60%.

Insider Buying and Selling

In related news, CEO Jack Bendheim sold 4,528 shares of Phibro Animal Health stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $48.49, for a total transaction of $219,562.72. Following the completion of the sale, the chief executive officer owned 56,152 shares in the company, valued at approximately $2,722,810.48. This trade represents a 7.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 89,008 shares of company stock worth $4,757,177. Company insiders own 50.13% of the company’s stock.

Institutional Trading of Phibro Animal Health

A number of hedge funds have recently added to or reduced their stakes in PAHC. Millennium Management LLC boosted its stake in Phibro Animal Health by 4,227.1% in the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock worth $23,959,000 after buying an additional 626,492 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Phibro Animal Health by 1,730.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after buying an additional 225,110 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Phibro Animal Health by 145.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 286,172 shares of the company’s stock worth $15,671,000 after buying an additional 169,628 shares during the last quarter. Castleark Management LLC acquired a new stake in Phibro Animal Health in the 1st quarter worth about $7,904,000. Finally, Advisors Preferred LLC acquired a new stake in Phibro Animal Health in the 3rd quarter worth about $3,953,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health News Roundup

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks Research lifted multiple EPS estimates for Phibro Animal Health, including FY2026, FY2027, FY2028, and several quarterly periods, while maintaining a Strong-Buy rating, which suggests analysts see improving earnings power.
• Neutral Sentiment: Phibro Animal Health will present at the Stifel Jaws & Paws Conference on May 27, which could provide new commentary on operations and strategy, but the event itself does not change fundamentals yet. Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
• Negative Sentiment: Recent reports said Citi reduced its price target on PAHC to $44 from $62, reflecting softer valuation sentiment in the sector. Phibro Animal Health Corporation (PAHC) Price Target Cut to $44 by Citi Amid Sector Pressure

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.